Jubilant Pharmova : Investor Presentation- March 12, 2024

Investor Presentation

March, 2024

Jubilant Pharmova is uniquely positioned to create sustained Shareholder Value

An integrated global	Over 5,500 people globally,	6 manufacturing facilities catering	Strong position in Radiopharmaceuticals,
pharmaceuticals and contract	including over 2,100 in	to regulated markets including USA,	Allergy Immunotherapy and CDMO
research company	North America	Europe and other geographies	Sterile Injectables

One of the leading and growing	Proprietary business has strong	Drug Discovery services through	FY23 Revenue ~Rs 6,300 Cr.
India based Contract Research and	portfolio of programs in oncology	two world-class centers in	(~US$ 783 million)
Development company	and auto immune disorders	Bengaluru and Greater Noida

1

Business Structure

Jubilant Pharmova Limited

Radiopharma	CRDMO	CDMO Sterile	Generics	Allergy	Proprietary
Injectables	Immunotherapy	Novel Drugs

Radiopharmaceuticals Radiopharmacies

Drug Discovery	CDMO - API
Services

2

9M'FY24 - Segment Wise Revenue Split

Allergy Immunotherapy

10%

Generics	Radiopharma
44%
12%

CDMO Sterile

Injectables

17%CRDMO

17%

3

Business Snapshot

• #3 radiopharmaceutical manufacturer in the US
• Manufacturing facility based in Montreal Canada
• # 2 network in the US with 46 radiopharmacies

• #2 player in the US allergenic extract market
• Sole supplier of venom in the
  US
• Manufacturing facility at Spokane, WA, US

• Leading contract manufacturer for Sterile Injectables
• Differentiated technologies, viz. hormonal steroids, vaccines
• Manufacturing facilities in Spokane and Montreal

• Manufacturing facilities at Roorkee, India and Salisbury, US
• Focus on quality leadership and compliances
• Market leadership in select products in US and branded markets

Radiopharma

Allergy Immunotherapy

CDMO - Sterile Injectables

Generics

• Fully integrated Drug Discovery services provider
• Facilities in Greater Noida and Bengaluru
• Provides Drug Discovery and CDMO services to global innovators

• Manufacturing facility at Nanjangud, India
• Over 50% of API sales are to regulated markets
• Strong market share in CNS / CVS products globally

• High potential programs in the area of oncology and autoimmune disorders
• Lead program LSD1/HDAC6 inhibitor initial phase 1 data suggests therapeutic potential
• IND approval for second program, JBI-778, an Oral, Brain Penetrant PRMT5 Inhibitor

Drug Discovery Services

CDMO - API

Proprietary Novel Drugs

4

High-Quality,World-Class Manufacturing Footprint and Operational Facilities

Spokane, Washington, USA

• Contract manufacturing of Sterile

injectable and Allergy therapy

Salisbury, Maryland, USA

 Solid Dosage Formulations

(Tablets & Capsules)

Biosys Gr. Noida

Facility

Roorkee, Uttarakhand

 Generics manufacturing

Noida

Montreal, CanadaCorporate Office

 Contract Manufacturing of

Sterile Injectables and non-

Sterile Products

Montreal, Canada				Nanjangud, Karnataka
 Radiopharmaceuticals
					 API manufacturing

Biosys Bangalore

Facility

Pharmaceuticals Manufacturing Facilities Biosys Facilities

• 6 manufacturing facilities catering to the regulated markets, including USA, Europe and other geographies.
• Contract research and development services through 2 world-class research centers in Bengaluru and Greater Noida in India.

5

Financial Highlights

Q3 & 9M'FY24

Jubilant Pharmova Limited

Financial Results

Overview Q3'FY24

- Consolidated

			Figures in Rs Cr.
Particulars	Q3'FY23	Q2'FY24		Q3'FY24
Total Income	1,562	1,690		1,713
EBITDA	155	252		254
EBITDA Margin (%)	9.9%	14.9%		14.8%
Share of profit / (loss) of associates	(2)	9		13
PBT	9	98		101
PBT Margin	0.6%	5.8%		5.9%
PAT	(16)	62		66

• Total Income grew by 10% YoY to Rs. 1,713 Cr.
• EBITDA grew by 63% YoY to Rs. 254 Cr. and EBITDA margins expanded by 490 bps YoY
• PAT at Rs. 66 Cr. on improved operating performance & higher share of profit from

associates ( Majority contributed by Sofie Biosciences Inc.)	7

Financial Results

Overview 9M'FY24

- Consolidated

		Figures in Rs Cr.
Particulars	9M'FY23	9M'FY24
Total Income	4,638	4,999
EBITDA	591	684
EBITDA Margin (%)	12.7%	13.7%
Share of profit / (loss) of associates	(5)	21
Exceptional Items on bonds refinancing	(57)	0
PBT	114	224
PBT Margin	2.5%	4.5%
PAT	36	135
Normalised PAT1	92	135

• Total Income grew by 8% YoY to Rs. 4,999 Cr.
• EBITDA grew by 16% YoY to Rs. 684 Cr. and EBITDA margins expanded by 100 bps YoY
• EBITDA 9M'FY23 included one time gain (Rs. 87 Cr.) due to Covid related business

1. Normalised PAT is after adjusting for exceptional item

8

Debt 9M'FY24

- Consolidated

			Figures in Rs Cr.
Particulars	Mar 31, 2023	Sep 30, 2023	Dec 31, 2023
Long Term*	3,152	3,202	3,211
Short Term	258	218	208
Total Gross Debt	3,410	3,420	3,419
Total Gross Debt (On constant currency )	3,410	3,388	3,381
* Excluding Debt Initiation Cost

Exchange Rate : 1 USD = INR 82.17 on Mar 31,2023, 1 USD = INR 83.04 on Sep 30,2023, 1 USD = INR 83.21 on Dec 31,2023

9